Across TCGA pan-cancer cohorts, CYP2C8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2C8 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CYP2C8 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP2C8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
UCEC, COAD, and LGG are the cancer types where CYP2C8 Mutation most reproducibly stratifies survival.